On December 16, 2025, Tolmar, Inc., a specialty pharmaceutical company, inaugurated its new Northern Illinois Laboratory at Rosalind Franklin University’s Innovation and Research Park (IRP) in North Chicago, Illinois. This facility is designed to enhance Tolmar’s capabilities in developing and commercializing pharmaceutical products while strengthening the university’s commitment to industry innovation.
Founded in 2007, Tolmar is internationally recognized for its expertise in long-acting injectable drug delivery systems. The company specializes in developing and manufacturing injectables focused on urology, oncology, and endocrinology. Notably, Tolmar’s leading product, utilized in treating advanced prostate cancer, is available in 89 countries.
New Facility Signifies Growth and Collaboration
The Northern Illinois Laboratory will complement Tolmar’s existing research capabilities in Colorado, expanding its regional presence and facilitating further collaboration with local researchers. According to Dr. Dave Loffredo, the company’s Vice President of Innovation, “Tolmar is excited to expand our development capability, now covering both Colorado and Illinois.” He expressed enthusiasm for the opportunities that the IRP presents and emphasized the company’s eagerness to integrate into the vibrant research community at the university.
Dr. Stace Porter, Senior Vice President of Development Operations for Tolmar, highlighted the advantages of the new facility. “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores,” he stated. The lab’s location within Lake County, a hub for global life science companies, positions Tolmar favorably for future growth.
Strengthening Research and Development Ecosystem
The IRP spans 100,000 square feet and hosts six research centers, including the Center for Cancer Cell Biology, Immunology, and Infection. Dr. Joseph DiMario, Executive Vice President for Research at Rosalind Franklin University, expressed optimism about the new partnership. “We look forward to collaborations that can help accelerate new product development,” he stated. He noted that the IRP fosters an environment conducive to innovative research, which he described as “intellectual biomedical collisions” that drive meaningful advancements.
Tolmar’s new laboratory signifies a major step in the company’s ongoing commitment to innovation within the pharmaceutical landscape. By establishing this facility at Rosalind Franklin University, Tolmar reinforces its dedication to addressing critical health challenges while also contributing to the region’s reputation as a leader in life sciences.
For more information about Tolmar, visit www.tolmar.com and for insights into Rosalind Franklin University, explore rosalindfranklin.edu.
